Skip to main content
Top
Published in: Medical Oncology 3/2015

01-03-2015 | Original Paper

Radiation sensitization with sodium nitrite in patients with brain metastases: a pilot randomized controlled trial

Authors: Seyed Mohammad Hosseini, Shole Arvandi, Sasan Razmjoo, Hodjatollah Shahbazian, Fakher Rahim, Tohid Rafie, Maedeh Barahman, Ali Bagheri

Published in: Medical Oncology | Issue 3/2015

Login to get access

Abstract

Systemic administration of nitrite anion seems to be a practical way to produce local burst of nitric oxide, a hypoxic cell radiosensitizer in solid tumors. This randomized controlled pilot study assessed radiologic objective response rate (ORR) in patients suffered from brain metastases treated by whole-brain radiotherapy (WBRT) concurrent with intravenous infusion of sodium nitrite versus WBRT alone. Twenty patients were randomized into the following groups: Ten patients treated by WBRT (30 Gy in ten fractions over 2 weeks) concomitant with 2-hour intravenous infusion of sodium nitrite (267 µg/kg/h) before each fraction of radiation (WBRT + SN arm) and ten patients received the same schedule of WBRT, alone (control arm). ORR was measured according to response evaluation criteria in solid tumors (RECIST version 1.1). There were four radiologic objective responses in WBRT + SN arm compared with three in the control group without significant statistical difference (P = 1.00). In contrast, age ≤ 65years (P = 0.05) and presence of extra-cranial metastases (P = 0.01) were predictor factors of ORR. In conclusion, intravenous infusion of sodium nitrite with this dose and schedule to patients with brain metastases concurrent with radiotherapy did not show any major benefit in terms of radiologic response.
Literature
1.
go back to reference Hall EJ. Radiobiology for the radiologist. 7th ed. Hagerstown: LWW; 2011. Hall EJ. Radiobiology for the radiologist. 7th ed. Hagerstown: LWW; 2011.
2.
go back to reference Jordan BF, Sonveaux P, Feron O, Gregoire V, Beghein N, Dessy C, et al. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer. 2004;109(5):768–73.CrossRefPubMed Jordan BF, Sonveaux P, Feron O, Gregoire V, Beghein N, Dessy C, et al. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer. 2004;109(5):768–73.CrossRefPubMed
4.
go back to reference Folkes LK, O’Neill P. DNA damage induced by nitric oxide during ionizing radiation is enhanced at replication. Nitric Oxide. 2013;34:47–55.CrossRefPubMed Folkes LK, O’Neill P. DNA damage induced by nitric oxide during ionizing radiation is enhanced at replication. Nitric Oxide. 2013;34:47–55.CrossRefPubMed
5.
go back to reference Frerart F, Sonveaux P, Rath G, Smoos A, Meqor A, Charlier N, et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin Cancer Res. 2008;14(9):2768–74.CrossRefPubMed Frerart F, Sonveaux P, Rath G, Smoos A, Meqor A, Charlier N, et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin Cancer Res. 2008;14(9):2768–74.CrossRefPubMed
6.
go back to reference Sonveaux P, Jordan BF, Gallez B, Feron O. Nitric oxide delivery to cancer: why and how? Eur J Cancer. 2009;45(8):1352–69.CrossRefPubMed Sonveaux P, Jordan BF, Gallez B, Feron O. Nitric oxide delivery to cancer: why and how? Eur J Cancer. 2009;45(8):1352–69.CrossRefPubMed
7.
go back to reference Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One. 2011;6(1):e14504.PubMedCentralCrossRefPubMed Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One. 2011;6(1):e14504.PubMedCentralCrossRefPubMed
8.
go back to reference Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.CrossRefPubMed Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.CrossRefPubMed
9.
go back to reference Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103–14.PubMedCentralCrossRefPubMed Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103–14.PubMedCentralCrossRefPubMed
10.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
11.
go back to reference Ree AH, Hollywood D. Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. Radiother Oncol. 2013;108(1):3–16.CrossRefPubMed Ree AH, Hollywood D. Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. Radiother Oncol. 2013;108(1):3–16.CrossRefPubMed
12.
go back to reference Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 1993;53(24):5845–8.PubMed Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 1993;53(24):5845–8.PubMed
13.
go back to reference De Ridder M, Verellen D, Verovski V, Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide. 2008;19(2):164–9.CrossRefPubMed De Ridder M, Verellen D, Verovski V, Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide. 2008;19(2):164–9.CrossRefPubMed
14.
go back to reference Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ. Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res. 2009;28:1.PubMedCentralCrossRefPubMed Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ. Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res. 2009;28:1.PubMedCentralCrossRefPubMed
15.
go back to reference Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta O, Mohar A. Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. Radiother Oncol. 2012;102(2):187–91.CrossRefPubMed Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta O, Mohar A. Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. Radiother Oncol. 2012;102(2):187–91.CrossRefPubMed
Metadata
Title
Radiation sensitization with sodium nitrite in patients with brain metastases: a pilot randomized controlled trial
Authors
Seyed Mohammad Hosseini
Shole Arvandi
Sasan Razmjoo
Hodjatollah Shahbazian
Fakher Rahim
Tohid Rafie
Maedeh Barahman
Ali Bagheri
Publication date
01-03-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0493-2

Other articles of this Issue 3/2015

Medical Oncology 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.